Tuberculosis is the leading cause of death by an infectious disease worldwide 1 . However, the involvement of innate lymphoid cells (ILCs) in immune responses to infection with Mycobacterium tuberculosis (Mtb) is unknown. Here we show that circulating subsets of ILCs are depleted from the blood of participants with pulmonary tuberculosis and restored upon treatment. Tuberculosis increased accumulation of ILC subsets in the human lung, coinciding with a robust transcriptional response to infection, including a role in orchestrating the recruitment of immune subsets. Using mouse models, we show that group 3 ILCs (ILC3s) accumulated rapidly in Mtb-infected lungs and coincided with the accumulation of alveolar macrophages. Notably, mice that lacked ILC3s exhibited a reduction in the accumulation of early alveolar macrophages and decreased Mtb control. We show that the C-X-C motif chemokine receptor 5 (CXCR5)-C-X-C motif chemokine ligand 13 (CXCL13) axis is involved in Mtb control, as infection upregulates CXCR5 on circulating ILC3s and increases plasma levels of its ligand, CXCL13, in humans. Moreover, interleukin-23-dependent expansion of ILC3s in mice and production of interleukin-17 and interleukin-22 were found to be critical inducers of lung CXCL13, early innate immunity and the formation of protective lymphoid follicles within granulomas. Thus, we demonstrate an early protective role for ILC3s in immunity to Mtb infection.
Using mouse models, we show that group 3 ILCs (ILC3s) accumulated rapidly in Mtb-infected lungs and coincided with the accumulation of alveolar macrophages. Notably, mice that lacked ILC3s exhibited a reduction in the accumulation of early alveolar macrophages and decreased Mtb control. We show that the C-X-C motif chemokine receptor 5 (CXCR5)-C-X-C motif chemokine ligand 13 (CXCL13) axis is involved in Mtb control, as infection upregulates CXCR5 on circulating ILC3s and increases plasma levels of its ligand, CXCL13, in humans. Moreover, interleukin-23-dependent expansion of ILC3s in mice and production of interleukin-17 and interleukin-22 were found to be critical inducers of lung CXCL13, early innate immunity and the formation of protective lymphoid follicles within granulomas. Thus, we demonstrate an early protective role for ILC3s in immunity to Mtb infection.
ILCs share features with both adaptive and innate immune cells and comprise three main subsets 2, 3 . Type 1 ILCs produce interferon (IFN)-γ and include natural killer (NK) cells and non-cytotoxic, non-NK type 1 ILCs 2, 3 . Group 2 ILCs, which produce interleukin (IL)-4, IL-5 and IL-13, are involved in inflammatory-linked airway hyperactivity, tissue repair and helminth clearance 2, 3 . ILC3s produce , and can participate in the strategic positioning of immune cells in ectopic lymphoid structures 5 . Circulating ILC3s are enriched for unipotent and multipotent ILC precursors, and can give rise to all known ILC subsets, including NK cells in vivo 6 . ILCs are crucial for tissue repair of the lungs following infection 7 and for generating hepatic granulomas 8 . Thus, we investigated the role of ILCs in the immune responses to tuberculosis. Using a validated flow cytometry panel (Extended Data Fig. 1 ), we found that blood ILCs were highly depleted in participants infected with tuberculosis compared to control participants, including the CD117 + ILC3 subset (Fig. 1a ), but not NK cells (Extended Data Fig. 2a ). ILC depletion was not exacerbated by drug resistance or coinfection with HIV ( Fig. 1a and Extended Data Fig. 2b ). Using paired samples from participants who were HIV − , we found that ILC1s and ILC3s rebounded after treatment, but ILC2s remained depleted (Fig. 1b) . Thus, in contrast to persistent infection with HIV 9 , circulating ILC1s and ILC3s were restored once the infection with Mtb was cleared, confirming a role for bacteraemia in modulating ILC accumulation. Whether ILC2s recover at a later time point remains to be tested. Depletion of blood ILCs during acute infection with HIV is associated with cell death 9 . However, infection with tuberculosis was not associated with significant changes in caspase-3 expression in ILCs (Extended Data Fig. 2c ), but with an increase in the anti-apoptotic marker B cell lymphoma 2 (BCL2) (Fig. 1c) . In addition, ILC2s showed a significant upregulation of CD25 (Fig. 1d) , a marker of activation and pro-survival phenotype in T cells 10 . These data suggest that circulating ILCs respond to infection with Mtb but are not lost from the blood due to cell death.
We next investigated whether ILCs accumulate in the lungs following infection with Mtb using a mouse model. C57BL/6 mice infected with aerosolized Mtb showed rapid early accumulation of ILC3s, but not ILC1s, with later accumulation of ILC2s (Fig. 2a and Extended Data Fig. 3 ) and the number of ILC3s increased as infection proceeded (Fig. 2a) . Simililarly, an ILC3 subset that expressed RAR-related orphan receptor γ-t (Rorγt)-GFP also accumulated during Mtb infection in C57BL/6 mice ( Fig. 2b) . Notably, accumulation of ILC3s coincided with accumulation of alveolar macrophages, and preceded the accumulation of monocytes and recruited macrophages ( Fig. 2c) and Mtb control in the lung (Fig. 2d) . To confirm these observations in humans, we next examined fresh lung tissue, which was surgically resected from participants infected with tuberculosis and identified tissue-resident ILCs using established markers (Extended Data Figs. 1, 4a ). In the lung tissue, in contrast to our findings in the blood, all ILC subsets, including NK-p44 + and NK-p44 − ILC3 subpopulations, but not NK cells, were increased compared to healthy lung tissue margins from Letter reSeArCH lungs of controls who were not infected with tuberculosis (Fig. 2e and Extended Data Fig. 4b, c) . Notably, this was not affected by HIV coinfection (Extended Data Fig. 4d ). Together, our results show that although circulating ILCs are reduced during pulmonary tuberculosis, they are rapidly increased upon infection in mice and accumulate in the lungs of both Mtb-infected mice and human participants who are infected with Mtb.
The chemokine CXCL13 is induced in mouse and human lungs during infection with tuberculosis 11 and recruits lymphocytes through CXCR5 to mediate their spatial organization within lymphoid structures called inducible bronchus-associated lymphoid tissues (iBALT)
11
. Consistent with this, high levels of CXCL13 were detected in the plasma of participants with pulmonary tuberculosis, and these were reduced following tuberculosis treatment (Fig. 2f) , irrespective of coinfection with HIV (Extended Data Fig. 4e ). Furthermore, CXCR5 expression on all human blood ILC subsets was increased (Fig. 2g) , and in addition CD103 expression (Extended Data Fig. 4f ), a tissue-resident lymphocyte marker, was also increased. Subsequently, we detected distinct 
Fig. 1 | Circulating ILCs are depleted and activated in response to tuberculosis. a, Circulating ILC subsets were enumerated in blood of 50 participants with tuberculosis who were HIV + (n = 28) or HIV − (n = 22), and healthy controls (n = 19) by flow cytometry. Significance was determined by KruskalWallis test with corrections for multiple comparisons. b, Paired ILC subsets in the blood before and after standard tuberculosis treatment (n = 12) were compared to frequencies in healthy controls (n = 19; P value by Wilcoxon matched-pairs test). Pre-TRT, untreated; TRT, after treatment. c, The median fluorescent intensity (MFI) of the anti-apoptotic marker BCL2 was measured in participants who were tuberculosis-positive (n = 15-16) and control participants (n = 16) on all ILC subsets, and in CD56 high NK cells, but not CD56 low NK cells, CD4 + , CD4 − CD3 + T cells and CD19-expressing B cells. Significance was determined by unpaired Mann-Whitney U-test with Bonferroni corrections. d, Expression of activation and pro-survival marker CD25 was determined using flow cytometry in ILC subsets in blood from participants with tuberculosis who were HIV − (n = 19). Significance was determined by Kruskal-Wallis test with corrections for multiple comparisons. ). *P < 0.05, **P < 0.01, ****P < 0.0001. Significance was determined by Student's t-test (a-c) and all experiments were repeated at least three times. e, Human ILC subsets were measured in tuberculosis-infected lung tissue (TB + ) compared to tuberculosis-negative (TB − ) control lung tissue, and in the circulation using flow cytometry. Significance was determined by Kruskal-Wallis test with adjustments for multiple comparisons. f, CXCL13 protein levels were measured in plasma from subjects with drug-susceptible tuberculosis, and after 6 months of standard tuberculosis treatment (two-tailed Wilcoxon matched-pairs test). g, CXCR5 expression was measured on circulating ILC subsets using flow cytometry. Significance was determined by MannWhitney U-test with correction for multiple comparisons; only P values that were significant after correction are shown. h, ILC3 quantification in the formalin-fixed paraffin-embedded lung sections from human, nonhuman primates (latent tuberculosis and pulmonary tuberculosis) was carried out by staining with CD3, B220 Letter reSeArCH populations of CXCR5-expressing ILC3s, and CD103-expressing ILC2s and ILC3s in lung tissue of participants with tuberculosis (Extended Data Fig. 4g ). Notably, mouse and human ILCs migrated in response to CXCL13, and this was found to be CXCR5-dependent in mouse ILC3s (Extended Data Fig. 4h, i) . Given the role of CXCR5 in iBALT formation, we hypothesized that ILC3s would localize within iBALTcontaining tuberculosis lung granulomas. In histological sections from human participants with pulmonary tuberculosis, we confirmed the enrichment of CD3 − RORγt + and CD3 − CD127 + ILC3s but not CD3
+

RORγt
+ (T helper 17 (T H 17) cells) within granulomaassociated lymphoid follicles compared to the low numbers of CD3 − RORγt + ILC3s in necrotic tuberculosis granulomas and non-tuberculosis influenza-infected lung tissue ( Fig. 2h and Extended Data Fig. 5a-d 
+ ILC3s localized significantly within the non-necrotic well-formed iBALT-containing tuberculosis granulomas of macaques with latent tuberculosis infections, but not within necrotic granulomas in macaques with pulmonary tuberculosis ( Fig. 2h and Extended Data Fig. 5e ). These data together show that the CXCL13-CXCR5 axis is involved in functional recruitment of lung ILC3s after infection with Mtb and in the localization of ILC3s to iBALT-associated granulomas.
Next, to characterize human lung ILCs, we performed RNA sequencing on ILC2s and ILC3s sorted from fresh resected lungs of participants who were infected with Mtb and two controls (sorted based on Extended Data Fig. 1 ; sort purity shown in Extended Data Fig. 6 ). Differential expression analysis of ILC2s (45 significant differentially expressed genes) highlighted ILC2 genes that are indicative of inflammatory signalling (IL13 and IL1RL1), tissue repair (amphiregulin (AREG)) ( Fig. 3a Fig. 3a and Supplementary Table 2 ), including RORC and natural cytotoxic receptor 3 (NCR3) and genes encoding pro-inflammatory cytokines (IL1B, colony stimulating factor 3 (CSF3) and oncostatin M (OSM)), which are associated with pulmonary tuberculosis and innate cell recruitment 14, 15 . Accordingly, 7 chemokine genes, including CXCL1 and CXCL5, which are central to neutrophil recruitment in pulmonary tuberculosis 16 and the monocyte chemoattractants CXCL17 and CCL2 (which encodes sMCP-1) were all upregulated (Fig. 3b) . Next, we identified potential upstream regulators of these responses by pathway analysis (Fig. 3c and Supplementary Tables 3, 4) . The predicted top upstream drivers of the transcriptional profile that were observed in sorted ILC2s were IL-17, IL-6, CSF-1 and C-type lectin domain family 7 member A (CLEC7A), pathways implicated in pulmonary tuberculosis [17] [18] [19] , and vasoactive intestinal peptide (VIP), which is known to be elevated during lung inflammation and interacts with the ILC2 marker chemoattractant receptor homologous molecule expressed on T helper type 2 (CRTH2) 20 . As VIP had not been directly linked to tuberculosis, we confirmed protein expression in lung tissue from participants with tuberculosis (Extended Data Fig. 7a ). Top predicted upstream drivers of ILC3 responses are IFNγ, IL-1β, peroxisome proliferator-activated receptor (PPAR)-γ and hepatocyte nuclear factor (HNF)-4-which have all previously been associated with the tuberculosis immune response 21, 22 -and OSM. The latter is less well-studied in tuberculosis infection; however, it is detected in human granuolma 23 and can be seen in the lung tissue sections that were examined in this study (Extended Data Fig. 7b ). Construction of gene interaction networks between our differentially expressed genes, and other published gene interactions, suggest that OSM may be linked to other major inflammatory cytokines, and inducers of cell growth and proliferation (Extended Data Fig. 7c and Supplementary Table 5 ). Moreover, genes downstream of OSM encompassed key immune-response pathways, including IFN signalling, IL-6-STAT and chemotaxis. Lastly, looking across all differentially expressed genes in ILC3s for enriched pathways that describe ILC3 responses (Extended Data Fig. 7d and Supplementary Table 6) highlights IL-17 signalling. Taken together, these transcriptional data from human lung ILCs from participants infected with tuberculosis show a clear response to infection and, in particular, support a role of ILC3s in coordinating lung immunity.
To address the mechanistic role of ILCs during Mtb infection, control mice, Rag1
−/− and Rag2
Il2rg −/− double-knockout mice were aerosol-infected with Mtb and early immune control was determined with tuberculosis (TB + , n = 5) compared to uninfected lungs from control participants is shown (TB − , n = 2). P values corrected using BenjaminiHochberg with a significance cut-off of false-discovery rate (FDR) < 0.01. c, Upstream drivers of differentially expressed genes in ILC2s and ILC3s were predicted using ingenuity pathway analysis. P values were calculated by hypergeometric test using data from the ingenuity pathway analysis.
Letter reSeArCH before accumulation of adaptive T cell responses occurred 24 . Whereas Rag1 −/− mice maintained early innate Mtb control similar to wild-type mice at 14 days after infection (d.p.i.), Rag2
Il2rg
−/− mice exhibited an increase in Mtb colony-forming units (CFUs) and this coincided with an absence of all lung ILC subsets (Fig. 4a, b) . Notably, increased early Mtb CFUs in Rag2
−/− mice could be rescued by adoptive transfer of sorted lung ILCs from Mtb-infected control mice that expressed Ccr6, Rorγt (also known as Rorc) and Ahr ( Fig. 4a and Extended Data Fig. 8a, b) . These results suggest that innate responses in Rag1 −/− mice are sufficient to mediate early Mtb control provided that common-γ chain-dependent ILCs are present. Furthermore, whereas Ifng −/− and Il13 −/− mice maintained Mtb control at 14 d.p.i. (Extended Data Fig. 9a ), no changes in any ILC subsets were observed (Extended Data Fig. 9b ). By contrast, Rorγt −/− mice exhibited increased early Mtb lung burden (Extended Data Fig. 9c ) and this coincided with decreased ILC3 accumulation, without affecting the ILC1 and ILC2 subsets (Extended Data Fig. 9d ). These results were further confirmed using mice with specific deletion of ILC3s-that is, Ahr 1,500 
Il2rg -/- 
ILC3s
, and CXCR5 + NKp46 + ILC3s were measured by flow cytometry (n = 5 C57BL/6 mice, n = 8 Il17 −/− Il22 −/− mice). i, Formalin-fixed paraffin-embedded lung sections were subjected to in situ hybridization with the mouse Cxcl13 probe and the area of Cxcl13 mRNA + signal per lung over the total lung area was quantified. j, k, C57BL/6 mice received IL-23 blocking antibody or isotype control antibody (by intraperitoneal injection) 1 day before infection with around 100 CFU Mtb and the lung bacterial burden (j) and numbers of alveolar macrophages, ILC2s and ILC3s (k)were quanified at 14 d.p.i. using plating and flow cytometry, respectively (n = 5 mice for isotype, n = 5-6 mice for anti-IL-23 antibody). Iso, isotype antibody. l, Formalin-fixed paraffin-embedded lung sections from Mtb-infected mice at 30 d.p.i. were stained with antibodies against B220 and CD3, and the average sizes of B cell follicles were quantified in Ahr f/f , Ahr f/f Rorγt cre , C57BL/6, Il17 −/− Il22 −/− doubleknockout, isotype antibody-treated C57BL/6 and anti-IL-23-antibodytreated C57BL/6 Mtb-infected mice. All data are mean ± s.d. Significance was determined by either one-way analysis of variance (ANOVA) (a-d) or Student's t-test (e-l). All experiments were replicated at least twice.
Letter reSeArCH Data Fig. 10f) . Furthermore, Il17 −/− Il22 −/− double-knockout mice displayed a significant early increase in lung Mtb burden (Fig. 4g) , decreased number of lung ILC3s as well as CXCR5 + ILC3s, but not ILC1s or ILC2s, and decreased expression of Cxcl13 mRNA within granulomas (Fig. 4h, i) . Accordingly, in vivo early neutralization of IL-23 in C57BL/6 mice resulted in increased early Mtb burden (Fig. 4j ) and reduced accumulation of early lung ILC3s (Fig. 4k) , when compared with isotype-control-treated C57BL/6 mice (Fig. 4j) . Notably, these early innate changes resulted in decreased formation of iBALT structures in all models (Ahr (Fig. 4l and Extended Data  Fig. 9g) . Similarly, Cxcr5 −/− mice also exhibited an increase in lung Mtb CFUs and decreased accumulation of ILC3s within lymphoid follicles, as well as decreased formation of iBALT structures (Extended Data Fig. 10g-i) . Taken together, these data support an unexpected protective role for ILC3s in regulating early Mtb control through the production of IL-17 and IL-22 and formation of iBALT structures in a CXCR5-dependent manner.
Here we show that circulating ILCs are activated and recruited to the lung during infection with tuberculosis in humans. Direct transcriptome sequencing of ILCs from fresh human tissue revealed a coordinated response to infection. These data, therefore, support the participation of ILCs in the human immune response to tuberculosis. Notably, we demonstrate the importance of ILC3s to the outcome of infection using multiple mouse models, showing that a reduction in lung ILC3s impaired early immune control of Mtb. The associated increase in lung bacterial burden coincided with decreased IL-17 and IL-22 production, compromised alveolar macrophage accumulation and impaired iBALT organization, which was dependent on the CXCR5-CXCL13 axis-which are key aspects of the immune response to Mtb. Taken together, our findings show that ILCs respond to Mtb infection and have an important role in determining the outcome of disease during tuberculosis.
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Data reporting. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment unless indicated otherwise. Participants. Tuberculosis-infected blood and plasma samples were obtained from the collection of urine, blood and sputum (CUBS) cohort, based at the Prince Cyril Zulu Communicable Disease Centre and the Nelson R. Mandela School of Medicine. In total, 50 blood samples were taken from participants with confirmed pulmonary tuberculosis (Gene Xpert, sputum smears or culture method), of which 28 were co-infected with HIV and 22 were HIV-negative. Control blood samples (TB − HIV − ) were collected from the Females Rising through Empowerment, Support and Health (FRESH) cohort from Umlazi, Durban.
Tuberculosis-affected lung tissue samples were obtained from 36 participants undergoing surgical resections due to severe lung complications, including haemoptysis, bronchiectasis, persistent cavitatory disease, shrunken or collapsed lung or drug-resistant infection, at the King Dinuzulu Hospital in Durban, KwaZuluNatal and Inkosi Albert Luthuli Central Hospital (IALCH) in Durban, KwaZuluNatal. In addition, 6 tuberculosis-negative control samples with macroscopically normal tissue margins from lung cancer resections or other inflammatory lung diseases from IALCH in Durban, KwaZulu-Natal were included in the study.
For some histological studies, lung sections were obtained from parcipants with tuberculosis from the Tuberculosis Outpatient Clinic at the National Institute of Respiratory Diseases (INER) in Mexico City. Samples were obtained from participants before anti-Mtb treatment.
All participants provided informed consent and each study was approved by the respective institutional review boards including the Biomedical Research Ethics Committee of the University of KwaZulu-Natal or INER. Sample preparation. Blood samples were processed from frozen peripheral blood mononuclear cells (PBMCs) purified using standard Ficoll separation. Samples were thawed in DNase-containing (25 units ml ) R10 (Sigma-Aldrich) at 37 °C. Cells were rinsed and rested at 37 °C for a minimum of 1 h before undergoing red-blood-cell lysis by 5-10 ml RBC lysis solution (Qiagen) for 20 min at room temperature. Cells were then stained with the appropriate antibody panel described in Flow cytometry.
Blood for plasma isolation was centrifuged at 2,000 r.p.m. for 10 min. The plasma layer was removed, frozen down in 1-ml aliquots and stored at −80 °C until needed. Later these samples were thawed at room temperature and vortexed thoroughly before use.
Lung samples were processed from fresh tissue immediately after surgery. Resected tissues were washed with cold HBSS (Sigma-Aldrich) and dissected into smaller pieces. Tissues were rinsed again and resuspended in 10 ml R10, containing DNase (1 μl ml −1 ) and collagenase (4 μl ml −1 ), and disassociated in a GentleMACS dissociator (Miltenyi Biotec). Cells were rested in a shaking incubator at 37 °C for 30 min and then further processed in the GentleMACS dissociator. After further resting (30 min at 37 °C) and washing steps, cells were strained through a 70-μm cell strainer and washed one final time. Cells were lysed using 5-10 ml RBC lysis buffer (Qiagen) and stained for flow cytometry analysis. Mtb infection in mice. C57BL/6, Ifng Rorγt cre mice were provided by M.C. The Mtb W. Beijing strain, HN878, was cultured to mid-log phase in Proskauer Beck medium containing 0.05% Tween-80 and frozen in 1-ml aliquots at −80 °C. Mice were infected with aerosolized around 100 CFU of bacteria using a Glas-Col airborne infection system. Lungs were collected, homogenized and serial dilutions of tissue homogenates were plated on 7H11 plates and the CFU was counted. Anti-IL-23 (Amgen, 16E5, 500 μg per mouse) and mouse IgG1 isotype (500 μg per mouse) were provided by Amgen and intraperitoneally injected into C57BL/6 mice one day before infection. Anti-NK1.1 (PK136, 100 μg per mouse) and mouse IgG2a isotype (100 μg per mouse) were provided by W.M.Y. and intraperitoneally injected on day 0 and every 3 days after infection. Male and female mice between the ages of 6 and 8 weeks were used for all mouse experiments. Sample sizes were chosen following empirical statistical power analysis based on previous published studies. Histological analysis following mouse experiments were subject to blind analysis. All mice were maintained and used in accordance with approved Washington University in St Louis Institutional Animal Care and Use Committee guidelines. Flow cytometry. ILCs from human blood and lung tissue were identified by a surface stain that included a near-infrared live/dead cell viability cell staining kit (Invitrogen) and the following monoclonal antibodies: CRTH2 (clone BM16, BD Biosciences), CD127 (clone R34.34, Beckman Coulter), CD117 (clone 104D2, BioLegend), CD56 (clone HCD56, BioLegend), CD25 (clone BC96, BioLegend), CD94 (clone HP-3D9, BD Biosciences), CD161 (clone HP-3G10, BioLegend), NK-p44 (clone Z231, Beckman Coulter), CD16 (clone 3G8, BioLegend), CD4 (clone RPA-T4, BD Biosciences) and CD45 (clone HI30, BD Biosciences). Lineage markers CD19 (clone HIB19, BD Biosciences), CD34 (clone 561, BioLegend), CD14 (clone HCD14, BioLegend), CD4 (clone OKT4, BioLegend), TCRαβ (clone IP26, BioLegend), TCRγδ (clone B1, BioLegend), BDCA2 (clone 201A, BioLegend) and FcER1 (clone AER-37 (CRA1), eBioscience). Intracellular stains were done after using a Fix/Perm kit (BD Biosciences) and included CD3 (clone UCHT1, BD Biosciences) or CD3 (clone HIT3A, BD Biosciences).
Modified antibody panels were used to stain for markers of apoptosis or lung homing. These panels consisted of a near-infrared live/dead cell viability cell staining kit (Invitrogen) and the following monoclonal antibodies: CD117 (clone 104D2, Biolegend), CD45 (clone HI30, BD Biosciences), CD161 (clone HP-3G10, BioLegend), CD56 (clone HCD56, BioLegend), CD94 (clone HP3D9, BD Bioscience), CD127 (clone R34.34, Beckman Coulter), CRTH2 (clone BM16, BD Biosciences), CD19 (SJ25C1, BD Bioscience), CD3 (OKT3, Biolegend) or CD69 (clone FNSO, BioLegend), CD4 (clone RPA-T4, BD Bioscience), CXCR3 (clone 1C6, BD Bioscience) or CD3 (clone UCHT1, BD Biosciences), CXCR5 (clone RF8B2, BD Bioscience) and CD103 (clone Ber-ACT8, Biolegend). Intracellular stains were done after using a Fix/Perm kit (BD Biosciences) and included caspase-3 (clone C92-605, BD Bioscience) and BCL2 (clone 100, BD Bioscience).
Cells were surface-stained with 25 μl of the appropriate antibody panel at room temperature in the dark, for 20 min. Following the BD Bioscience Fix/Perm step, cells were stained with the corresponding intracellular panel for a minimum of 20 min in the dark before being fixed with 2% paraformaldehyde. Fixed cells were acquired on a four-laser BD Fortessa flow cytometer (CUBS and fresh blood samples) or a five-laser FACSAria Fusion (lung, chemokine and apoptosis experiment samples) within 24 h of processing.
Mouse lung cell isolation and preparation were performed as described previously
11
. In brief, mice were asphyxiated with CO 2 and lungs were perfused with heparin in saline. Lungs were minced and incubated in collagenase/DNase (SigmaAldrich) for 30 min at 37 °C. Lungs were pushed through a 70-μm nylon screen to release cells. Following red-blood-cell lysis, cells were used for flow cytometry analysis. The following antibodies were from TonBo Biosciences: CD127 (clone A7R34), CD3 (clone 145-2C11) and CD19 (clone 1D3). Antibodies purchased from eBioscience were: RORc(γt) (clone AFKJS-9) and Sca-I (clone D7). CD45 (clone 30-F11), CCR6 (clone 140706), IL-17 (TC11-18H10), streptavidin and CXCR5 (clone 2G8) were purchased from Becton Dickinson. The following antibodies were from Invitrogen: biotinylated NKp46, TER-119 (clone TER-119), CD11c (clone N418), IL-22 (clone 1H8PWSR) and CD5 (clone 53-7.3) and CD11b (clone M1/70) from BioLegend. Live/dead AQUA was purchased from ThermoFisher Scientific. For intracellular staining, fixation/permeabilization concentrate and diluent (eBioscience) were used to fix and permeabilize lung cells for 20 min. The cells were incubated overnight with the intracellular staining. Samples were run on a four-laser BD Fortessa flow cytometer. All flow cytometry data were analysed using FlowJo version 9.7.6 (TreeStar). Adoptive transfer. Total ILCs (excluding ILC1, CD45 + CD127 + Lin − NK1.1 − ) were purified on a BD FACSJazz from the lungs of Mtb-infected C57BL/6 mice following enrichment for CD45 and staining with the above-mentioned antibodies. About 5,000 sorted and highly purified ILCs were intratracheally transferred into Rag2
Il2rg
−/− mice. ELISA. The Quantikine ELISA assay for human CXCL13/BLC/BCA-1 was used to measure the amount of CXCL13 in the plasma of 19 participants before and after 6 months of successful anti-tuberculosis treatment. Standards, controls and samples were run in triplicate. Results were measured at 450 nm using the GlowMax-Multi detection system (Promega). Concentrations were determined based on the standard curve generated on GraphPad Prism version 6.0 (GraphPad Software). Protein levels of mouse cytokines (IL-17, IL-22 and IL-23) in culture supernatants were measured using mouse ELISA kits or multiplex according to the manufacturer's instructions (R&D Systems, MBL International Corporation). In vitro chemotaxis assays. We sorted 10,000 human ILCs in duplicate (1 control and 1 experiment per individual) from PBMCs using the FACS panel described above, on a five-laser FACSAria Fusion. Cells were directly sorted into 100 μl of freshly prepared medium (HBSS containing 10% FBS) at 4 °C and transferred into the top well of a Corning HTS 24-well transwell plate. Bottom chambers of transwell plates were loaded with 600 μl of either medium alone, for controls, or medium containing 500 ng ml −1 recombinant human CXCL13 (R&D Systems), for experimental wells. Transwell plates were incubated for 2 h and then the aspirate from the bottom chamber was mixed with 50 μl of precision count beads (BioLegend) and acquired on a FACSAria Fusion. As antibody stains from the initial sort remained visible, ILC3s were identified and then counted using counting beads as per the manufacturers' instructions.
For the mouse chemotaxis assay, mouse ILCs (excluding ILC1, CD45
were sorted from Mtb-infected C57BL/6 mice after CD45 enrichment within the total lung cells using the staining panel described above, on a FACSJazz. Cells were directly sorted into 100 μl of freshly prepared medium (HBSS containing 10% FBS) at 4 °C and transferred into the top well of a Corning HTS 24-well transwell plate. Bottom chambers of transwell plates were loaded with 600 μl of either medium alone, for controls, or medium and 500 ng ml −1 of recombinant mouse CXCL13 (R&D Systems) for experimental wells. Transwell plates were incubated for 2 h and then the aspirate from the bottom chamber was stained using the ILC3 marker panel on a four-laser BD Fortessa flow cytometer to determine the exact number of ILC3s that migrated in response to the CXCL13 gradient. Multiplex fluorescent immunohistology. Fluorescent immunohistology was performed on histological sections of tuberculosis-infected lung tissues that were either supplied by P. Ramdial or prepared in-house from formalin-fixed lung tissue following resections. Sections were dried overnight at 60 °C and then processed using an Opal four-colour Manual IHC kit (Perkin Elmer) as per the manufacturer's instructions with antibodies against CD20 (1:400), CD3 (1:400) and CD127 (1:100), VIP (1:100) and OSM (1:100) as primary antibodies. Slides were scanned on a Zeiss Axio Observer microscope using TissueFAXS imaging software (Tissuegnostics) and analysed using TissueQuest analysis software (Tissuegnostics). Whole transcriptome amplification and RNA sequencing. ILC2 and ILC3 populations were sorted from lung tissue from five participants with tuberculosis and two participants with cancer (who acted as a control) using a five-laser FACSAria Fusion. A validated 17-colour FACS panel (Extended Data Fig. 1 ) and stringent gating was used to identify ILC2 and ILC3 populations in these samples. Cells were directly sorted into RLT buffer (Qiagen) containing 1% β-mercaptoethanol. Lysates were snap-frozen on dry ice and stored at −80 °C. As input numbers were low (50-1,385 cells), thawed lysate was split into three technical replicates for each sample to increase the probability of successful amplification. RNA extraction, cDNA conversion and whole-transcriptome amplification was carried out as previously described using Smart-seq2
9 . The quality of the amplified product was confirmed using a high-sensitivity DNA analysis kit and a 2100 BioAnalyzer (Aligent Technologies), and concentrations were measured using a Qubit assay kit (ThermoFisher Scientific). Diluted samples were tagmented, amplified and individually barcoded using a Nextera XT DNA Library prep kit (Illumina), cleaned using AMPure XP SPRI beads (Beckman Coulter) and sequenced on a NextSeq 500 (Illumina) using 30 × 30 PE reads with 8 × 8 index reads to an average depth of 14.9 × 10 6 reads. mRNA expression. RNA was extracted from the sorted mouse ILCs (CD45 + CD127 + Lin − NK1.1 − ) using the Qiagen RNeasy Mini kit (Qiagen). cDNA was generated using ABI reverse transcription reagents (ABI, ThermoFisher Scientific) and RT-PCR was run on a ViiA7 Real-Time PCR system (Life Technologies, ThermoFisher Scientific). The relative expression of Ccr6, Rorγt and Ahr in sorted ILCs was calculated over expression of Gapdh in each sample. The primer and probe sequences for mouse Gapdh were previously published 11 . The primer and probes for mouse Cccr6, Rorγt and Ahr were purchased from Applied Biosystems. RNA-sequencing data analysis. Sequencing data from the NextSeq 500 were demultiplexed and aligned against hg38 using TopHat
27
, and expression values, in counts, were generated in RSEM 28 for every sample. Samples with fewer than 10 6 aligned transcriptionally reads, or fewer than 10,000 measured genes, and genes expressed with fewer than five counts in fewer than four samples were discarded from subsequent analysis. Differential expression analysis was performed in R (build 3.3.2) using the DESeq2 package 29 (version 1.14.1) on ILC2s and ILC3s between samples (and replicates) from five individuals with tuberculosis and two individuals without tuberculosis. The DESeq2 results can be found in Supplementary Tables 1, 2 ; hits with FDR q < 0.01 were considered differentially expressed for downstream analyses. Differentially expressed genes and their significances and log-transformed fold changes for each comparison were then processed using Ingenuity Pathway Analysis (IPA) (Qiagen, https://www.qiagenbioinformatics.com/ products/ingenuity-pathway-analysis) to populate lists of predicted upstream drivers (Supplementary Tables 3, 4) . Upstream driver plots were generated from the 'upstream analysis' in IPA; hits with 'molecule type' including the word 'chemical' , 'P-value of overlap' > 0.01, and number of 'target molecules in data set' < 3 were excluded from plotting. The OSM upstream driver network was created using the mechanistic networks generated by IPA, using P < 0.01 for overlap significance. The downstream driver network for genes known to interact with OSM was generated using the ClueGO plugin 30 (version 2.3.3) in Cytoscape (version 3.3.0) with the following ontologies: Gene Ontology (GO) biological process, GO immune system process, KEGG (Kyoto Encyclopedia of Genes and Genomes) and Reactome pathways. Only pathways with significance of P < 0.01 after Benjamaini-Hochberg correction are shown, and a kappa score threshold of 0.45 was used to merge terms. The downstream pathway bar chart was generated using the 'downstream pathways' in IPA, for which large categories were manually annotated. All sequencing data have been deposited and are available from the Gene Epression Omnibus (GEO) repository, accession number GSE131031. ILC3 staining and quantification. Immunohistochemical staining of human, non-human primate and mouse formalin-fixed paraffin-embedded (FFPE) lung sections were initially dewaxed in xylene before hydrating with decreasing graded alcohol and methanol passages. Antigens were retrieved by heat treatment in 92 °C and EDTA buffer pH 8. Tissue staining with antibodies against RORγt (clone 6F3.1, Millipore for mouse; clone Q31-378, BD Bioscience for non-human primate and human), CD3 (clone SP7, ThermoFisher Scientific for human, non-human primate and mouse), PAX5 (clone 24/Pax-5, BD Pharmingen, for human and non-human primate) or B220 (clone RA3-6B2, BD Pharmingen) was performed for 1 h in a humid chamber. Tissues were washed in Tris-buffered saline pH 7.4-7.6 before incubation with secondary antibody (Novocastra Post Primary, Leica) and polymer (Novolink Polymer, Leica). To develop the reaction, tissues were incubated with 3,3′-diaminobenzidine chromogen (DAB, Leica). Single-stained sections (PAX5, B220) were incubated with DAB for 5 min and double-stained sections (RORγt and CD3) were incubated overnight. Tissues were counterstained with haematoxylin and rinsed in water. All tissues were mounted with coverslips using glycerol mounting medium. CD3
−
RORγt
+ ILC3s were quantified in the slides. Images were analysed manually by counting the number of ILC3s per field. The analysis was done in a blinded manner. Immunofluorescence staining and in situ hybridization. Mouse lung lobes were perfused with 10% formalin, fixed and paraffin embedded. In brief, the FFPE sections were processed to remove paraffin and then hydrated in 96% alcohol and phosphate-buffered saline. Antigens were retrieved with a DakoCytomation Target Retrieval Solution (Dako) and non-specific binding was blocked using 5% (v/v) normal donkey serum and Fc block (BD Pharmingen). Sections were then probed with anti-B220 (clone RA3-6B2, BD Pharmingen; dilution, 1:100) and anti-CD3 (clone M-20, Santa Cruz Biotechnology, Santa Cruz, CA; dilution, 1:100) antibodies to detect B cell follicle formation. For B cell follicles analyses, follicles were outlined with the automated tool of the Zeiss Axioplan 2 microscope (Zeiss), and total area and average size were calculated in μm 2 .
To detect CD3
− RORγt + ILC3s and CD20 + B cells in lungs of non-human primates 11 and humans infected with tuberculosis, slides were incubated with primary goat anti-CD3ε (clone M-20, Santa Cruz Biotechnology), mouse antihuman RORγt (clone 6F3.1, Milipore Sigma-Aldrich) and rabbit anti-human CD20 (LS-B2605-125, Lifespan Biosciences) antibodies. To detect CD3
−
RORγt
+ ILC3s and CD20
+ B cells in mouse lungs infected with Mtb, slides were incubated with primary goat anti-CD3ε (clone M-20, Santa Cruz Biotechnology), monoclonal rabbit anti-mouse RORγt (clone EPR20006, Abcam) and APC-rat anti-mouse CD45R (B220, clone RA3-6B2, BD Biosciences). Slides were incubated with primary antibodies overnight at room temperature in a humid chamber. The next day, slides were briefly washed in PBS, and primary antibodies were revealed with Alexa Fluor 568-conjugated donkey anti-goat IgG (A11057, ThermoFisher Scientific), FITC-conjugated donkey anti-mouse IgG (715-095-150, Jackson ImmunoResearch Laboratories), biotin-conjugated donkey anti-rabbit (711-065-162, Jackson ImmunoResearch Laboratories) or Alexa Fluor 568-conjugated donkey anti-goat IgG (A11057, ThermoFisher Scientific) and Alexa Fluor 488-conjugated donkey anti-rabbit IgG (711-546-152, Jackson ImmunoResearch Laboratories) for human or non-human primate slides or mouse slides, respectively. Finally, streptavidin Alexa Fluor 680 (S32358, ThermoFisher Scientific) was added to the slides to visualize CD20 for human or non-human primate sections. Slides were washed in PBS and mounted with Vectashield antifade mounting medium with DAPI (Vector Laboratories, H-1200). ILC3s were counted in 3−5 random 200× fields in each individual slide. Representative 200× images were taken with Axioplan Zeiss Microscope and recorded with a Hamamatsu camera.
FFPE lung sections were subjected to in situ hybridization with the mouse Cxcl13 probe using the RNAscope 2.5HD Detection Kit (Brown staining) as per the manufacturer's instructions (Advanced Cell Diagnostics). The representative images were captured with the Hamamatsu Nanozoomer 2.0 HT system with NDP scan image acquisition software. The Cxcl13 + area and total area per lobe was quantified in a 40× magnification. The ratio was calculated by dividing the Cxcl13 + area by total area on each lobe. Statistical analyses. Where MFI data were measured at different time points, MFI was converted to final relative MFI by normalizing each measurement to an internal control to standardize these measurements over time 31 . The Mann-Whitney U-test was used to determine statistical significance between two groups, with the exception of the human transwell data, which were analysed by one-tailed Wilcoxon signed-rank test; whereas significance between more than two groups was calculated using the Dunn's multiple comparisons test or a Mann-Whitney U-test with Bonferroni corrections. Comparisons between matched samples for which data were paired were analysed with the Wilcoxon matched-pairs signedrank test. All statistical analyses were performed using GraphPad Prism version 6.0d (GraphPad Software).
For mouse studies, differences between the means of two groups were analysed using two-tailed Student's t-test in Prism 5 (GraphPad). Differences between the means of three or more groups were analysed using one-way ANOVA with Tukey's post test. P < 0.05 was considered significant. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All relevant data are available from the corresponding authors upon reasonable request. RNA-sequencing data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) repository, accession number GSE131031. Fig. 1 n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
Extended Data
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability nature research | reporting summary
April 2018
Field-specific reporting All studies must disclose on these points even when the disclosure is negative.
Sample size
No prior sample size calculations were performed for human studies. For the blood analysis, similar sample numbers were used as in previous studies reporting statistical differences between blood ILC populations (Kloverpris et al. Immunity 2015) . For lung analysis, samples represent those collected over a 3 study period.
For animal studies, sample sizes were chosen following empirical statistical power analysis based on previous pilot studies ( Khader et al. 2007 Nat Immunol, Griffiths et al, 2016 etc) .
Data exclusions No human blood samples were excluded from analysis. Human lung samples were excluded if <10,000 viable CD45+ve leukocytes were detected by flow cytometry following sample processing. This was based on previous experience with lung tissue and was done prior to additional analysis steps. 6 lung sample in total were excluded on this basis.
Replication
For animal studies, all attempts at replication were successful.
Randomization Human subjects divided into those with active TB, previous TB or non-TB controls as reported in the manuscript.
For animal studies, no method of randomization was used.
Blinding
Blinding was not possible for human subjects due to the nature of sample collection and processing. For animal studies, J.R-M. was blinded during the histological analyses.
Reporting for specific materials, systems and methods All the antibodies used in human and mouse experiment is reported in methods in the "Flow cytometry" sections.
Validation
All antibodies commercially available flow cytometry antibodies for staining primary human or mouse samples and validated by the manufacturer. All antibodies titrated in house and compatibility with the flow panel confirmed by FMO staining.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
The description of research animals used is reported in the methods in the "Mice" section. 
Wild animals
